Navigation Links
Results of Study in Pre-School Children Published in Clinical Pediatrics Adds to Support for Importance of Dietary DHA Intake
Date:6/26/2008

hs. DHA blood levels were measured using a new finger-stick blood test designed by Martek. Cognitive function was measured with four tests, including the PPVT-III. Tests were administered by licensed psychologists with at least of five years of pediatric experience.

"The results of this research are promising and highlight the need to further investigate the relationship between DHA and cognitive development and performance in children," said Dr. Richard Litov, director of Pedia Research L.L.C., and a lead investigator for the study. "This is especially important in light of the fact that most U.S. children get less than 30 mg of DHA per day through diet, far less than what many experts recommend."

DHA (docosahexaenoic acid) omega-3 is a long-chain omega-3 fatty acid that serves as a primary building block for the brain and the eyes and supports brain, eye and cardiovascular health throughout life. There is a large and growing body of scientific evidence demonstrating that people of all ages, from infants to aging adults, benefit from an adequate supply of DHA omega-3 in the diet. Scientific reviews highlight the importance of DHA omega-3 in proper brain and eye development and function, and clinical studies are underway to evaluate the role of DHA in decreasing the prevalence of certain neurological disorders. DHA is especially important for healthy growth and development during the early stages of life when the brain, eyes and nervous system are growing and developing at a rate unlike any other time in the human lifecycle. Studies have shown that babies who receive DHA supplementation exhibit a range of advantages over those who did not receive DHA supplementation, including cognitive and visual benefits. Yet despite its importance, Americans have among the lowest dietary intakes of DHA omega-3 in the world.

Fish are often thought to be the only source of DHA omega-3. However, life'sDHA offers a trusted, vegetarian form of DHA that contains no
'/>"/>

SOURCE Martek Biosciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
2. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Chindex International, Inc. Announces Fiscal 2008 Year End and Fourth Quarter Results
4. Helix BioPharma product development update, quarterly highlights and financial results for fiscal Q3 2008
5. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
6. ASCO Results: Oncologists Rank Genentech Number One
7. Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
8. Synthetech Announces Fiscal 2008 Results
9. Martek Announces Second Quarter 2008 Financial Results
10. Oramed Pharmaceuticals to Present Oral Insulin Trial Results at ADA Conference (June 6-10, San Francisco)
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Sigma-Aldrich Corporation (NASDAQ: SIAL ... the Hart-Scott-Rodino Antitrust Improvements Act (HSR Act) in ... 2014, thereby completing the U.S. HSR Act antitrust ... the Company by Merck KGaA, Darmstadt, Germany.  ... to closing the transaction, which remains subject to ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... ROCKVILLE, Md. , Dec. 22, 2014 ... MKT: SYN), a developer of pathogen-specific therapies ... focus on protecting the microbiome, today announced ... a Phase 1a clinical trial of SYN-004, ... the prevention of Clostridium difficile (C. ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... PharmAthene, Inc. (NYSE Amex: PIP ), a ... threats, today reported financial and operational results for the ... of 2009, PharmAthene recognized revenues of $5.5 million compared ... Revenues for the most recent quarter consisted primarily ...
... (OTC Bulletin Board: DORB) (DOR or the Company), a ... the first quarter of 2009. DOR,s revenues for the ... to $0.7 million for the first quarter of 2008. ... research and development amounts drawn down from DOR,s NIH ...
... Study and Orphan Drug DesignationROCKVILLE, Md., May 15 ... pharmaceutical company developing therapeutics for the treatment of cancer ... candidates at the American Society of Clinical Oncology (ASCO) ... 2, 2009 in Orlando, Florida. Presentations include both ...
Cached Biology Technology:PharmAthene Reports First Quarter 2009 Financial and Operational Results 2PharmAthene Reports First Quarter 2009 Financial and Operational Results 3PharmAthene Reports First Quarter 2009 Financial and Operational Results 4PharmAthene Reports First Quarter 2009 Financial and Operational Results 5PharmAthene Reports First Quarter 2009 Financial and Operational Results 6PharmAthene Reports First Quarter 2009 Financial and Operational Results 7DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 2DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 3DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 4DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments 5EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 2EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 3EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 4EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting 5
(Date:12/10/2014)... 9, 2014 CIE San Diego has launched ... the connective tissue that enhances care coordination among social ... share client-level information; earned a second $1 million grant ... serving seniors aging in community and; will be recognized ... 11 th 4-6p. CIE San Diego ...
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... 20, 2014 Strict laws against distracted driving ... the North American and European automotive sector towards gesture ... recognition systems that are intuitive and able to retrieve ... industry. New analysis from Frost & ... in Europe and ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... the speed that ice travels in more than 200 outlet ... the 21st century could be significantly less than the upper ... a paper funded by the National Science Foundation (NSF) and ... While the study indicates that a melting Greenland,s contributions to ...
... Boston, MA A new study by Harvard School of ... high-density lipoprotein (HDL) cholesterol, the so-called "good" cholesterol, may not ... be harmful. , This is the first study to ... resides on the surface of HDL cholesterol may increase the ...
... Scientists at Cold Spring Harbor Laboratory (CSHL) and Memorial ... that commonly occurring large chromosomal deletions that are ... functionally linked genes whose loss, they posit, confers a ... closely at one large deletion -- a so-called copy-number ...
Cached Biology News:Analysis of speed of Greenland glaciers gives new insight for rising sea level 2Analysis of speed of Greenland glaciers gives new insight for rising sea level 3Some HDL, or 'good' cholesterol, may not protect against heart disease 2Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers 2Clusters of cooperating tumor-suppressor genes are found in large regions deleted in common cancers 3
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
Homo sapiens jumping translocation breakpoint...
One-step, microplate or cuvet, colorimetric 530nm, detection limit 0.16mg/dL in serum or plasma. Procedure: 10 min....
MOUSE ANTI HUMAN NPM...
Biology Products: